Moreover, we further assessed the combined effects of NRAS and TAMs on the outcome of patients with HCC and found a lower OS rate in NRAS high CD68 high patients than in NRAS low CD68 high patients (Fig. 9D). The gene discussed is CD68; the disease is hepatocellular carcinoma.